Treatment of CRC cells with regorafenib for 24 hours gradually decreased the expression of p-STAT3Tyr705 and its related downstream survival targets cyclin D1 and Mcl-1 in a dose-dependent manner (Figure 2A). Here, CCND1 is linked to colorectal carcinoma.